Comment: "In The Lancet Psychiatry, Ilina Singh and colleagues1 argue that, despite a paucity of research data, it is ethically permissible for clinicians to prescribe ketamine for severe, treatment-resistant depression outside of clinical trials, as long as several regulatory conditions are met.1 The arguments they posit are persuasive, but in this Comment we examine both practical and ethical issues that might give readers pause before accepting their conclusions." Please contact the library to request a copy of this article - http://bit.ly/1Xyazai